INTRODUCTION
============

Bullous pemphigoid (BP) is an autoimmune disease where autoantibodies target structural proteins at the dermal--epidermal junction. Two hemidesmosomal proteins, 230 kDa protein and 180 kDa antigen, have been identified as the major targets of BP autoantibodies. BP manifests with tense blisters on the skin^\[[@b1-1207-1-9079-1-10-20190909]\]^. It is poorly understood although many trigger factors have been identified, such as contrast material injection, surgical procedures, mechanical trauma, insect bites, thermal burns, radiotherapy and ultraviolet exposure associated with pre-existing psoriasis^\[[@b2-1207-1-9079-1-10-20190909]\]^. Linagliptin is one of the new dipeptidyl peptidase-4 (DPP-4) inhibitors used in the treatment of type 2 diabetes mellitus (DM). DPP-4 inhibitors have been recently implicated in inducing BP, but the mechanism is not entirely clear. DPP-4 inhibitors may induce anti-basement membrane zone antibodies or other structurally similar antibodies, leading to sub-epidermal bullae and BP^\[[@b3-1207-1-9079-1-10-20190909]\]^. Many recent case reports show that use of DPP-4 inhibitors is a risk factor for BP onset, but there is no evidence of an association with alopecia.

CASE DESCRIPTION
================

A 68-year-old Caucasian man with a complex medical history including type 2 DM presented to the emergency department with a 3--4-week history of generalized pruritus, new onset diffuse alopecia and diffuse bullae over his trunk, arms and legs. The patient initially had developed bullae and blisters over his legs. Simultaneously, he noticed a significant loss of his scalp and beard hair as well as his eyebrows. This was accompanied by intense pruritus over the abdomen and back for approximately 2 weeks prior to the development of the bullae. The intense itching, development of further bullae, and almost complete alopecia prompted the patient to present to the emergency department.

A review of his history did not reveal any drug allergies and he denied a family history of autoimmune conditions. He had not travelled anywhere recently and did not present with any constitutional symptoms or myalgias. His home medications included linagliptin, allopurinol, amlodipine, atorvastatin, furosemide, hydralazine, levothyroxine, pantoprazole, rivaroxaban, terazosin and insulin.

His vital signs were all within normal limits: he was afebrile at 36.8°C, his heart rate was 59 bpm, blood pressure was 118/73 mmHg, and oxygen saturation was 98% on room air. Physical examination revealed bullae over his back, abdomen and both lower legs and measuring approximately 1--3 cm in diameter ([Fig. 1](#f1-1207-1-9079-1-10-20190909){ref-type="fig"}). He also had numerous smaller bullae over both flanks, upper arms and lower legs and measuring approximately 0.5--1 cm in diameter. There was no specific dermatomal distribution and no oral ulcerations or mucositis. The patient had diffuse alopecia on his scalp, eyebrows and beard. There was no erythema, scaling or scarring associated with the hair loss ([Fig. 2](#f2-1207-1-9079-1-10-20190909){ref-type="fig"}).

Investigations
--------------

Initial laboratory investigations revealed an elevated creatinine level of 300 mmol/l (baseline in the mid-200s) with normal electrolytes. The patient also had an elevated CRP level of 12.6 mg/l, his white blood cell count was normal at 10.3 g/l, and haemoglobin concentration was 110 g/l.

Hospital course
---------------

Skin biopsies performed on admission showed sub-epidermal blisters with multiple eosinophils highly suggestive of BP ([Fig. 3](#f3-1207-1-9079-1-10-20190909){ref-type="fig"}). Eosinophils are commonly seen in BP, but the diffuse eosinophilia seen in the biopsy specimen raised the possibility of drug-induced BP. Direct immunofluorescence showed deposition of IgG and C3 along the basement membrane confirming BP ([Fig. 4](#f4-1207-1-9079-1-10-20190909){ref-type="fig"}). Interestingly, linagliptin had been introduced a few months before the onset of cutaneous eruptions. At that point, linagliptin was highly suspected as the cause of BP and alopecia and therefore was discontinued. The patient was started on prednisone 40 mg with significant improvement of his skin lesions. He was then followed by the dermatology department and was started on mycophenolic acid (720 mg by mouth twice a day as a steroid-sparing agent) and topical clobetasol cream. At his 6-month follow-up, 80--90% of his skin lesions had resolved and his hair had grown back ([Fig. 5A,B](#f5-1207-1-9079-1-10-20190909){ref-type="fig"}).

DISCUSSION
==========

BP is not uncommon and has an incidence of 0.2--3/100,000 person-years with a higher incidence in older age groups. A UK study estimated the incidence there was 1.4/100,000 person-years^\[[@b4-1207-1-9079-1-10-20190909]\]^. There is a wide variation in mortality rate, with a 1-year mortality rate of 13--41% in Europe and 11--23% in the USA^\[[@b5-1207-1-9079-1-10-20190909]\]^. The classic manifestation of BP is diffuse tense blisters, but clinical presentation can also include diffuse urticarial or dermatitis plaques^\[[@b6-1207-1-9079-1-10-20190909]\]^.

DPP-4 inhibitors are a class of oral hypoglycaemic agents which can be used to treat type 2 DM. DPP-4 inhibitors work by increasing glucagon-like peptide-1 and glucose-dependent insulin-trophic polypeptide which leads to increased insulin and inhibits glucagon. Sitagliptin was the first agent of this class to be approved by the FDA in 2006^\[[@b7-1207-1-9079-1-10-20190909]\]^. The DPP-4 enzyme has many functions including biological roles in pro-inflammatory pathways^\[[@b8-1207-1-9079-1-10-20190909]\]^. DPP-4 is also known as CD26 and is widely expressed in various cell types throughout the body including the skin, but the role of the DPP-4 enzyme in autoimmune pathogenesis has not yet been clearly elucidated^\[[@b9-1207-1-9079-1-10-20190909],\ [@b10-1207-1-9079-1-10-20190909]\]^. A large observational study has indicated that the use of DPP-4 inhibitors is associated with an overall 75% increase in the risk of inflammatory bowel disease in patients with type 2 DM^\[[@b9-1207-1-9079-1-10-20190909]\]^. However, another large observational study indicated that DPP-4 inhibitor combination therapy appears to be associated with a decreased risk of autoimmune diseases, including rheumatoid arthritis, compared with non-DPP-4 inhibitor combination therapy^\[[@b11-1207-1-9079-1-10-20190909]\]^.

A few months after starting linagliptin, our patient developed alopecia areata totalis and a skin eruption shown to be BP by histological examination and immunofluorescence. Several cases of linagliptin-induced BP have been reported ([Table 1](#t1-1207-1-9079-1-10-20190909){ref-type="table"}). However, none of those cases described both alopecia areata and BP simultaneously due to linagliptin.

CONCLUSION
==========

This is the first report of linagliptin-associated alopecia areata and BP and may indicate a link between DPP-4 inhibitors and alopecia. Although DPP-4 inhibitors are known to be associated with BP, the pathogenesis is still not completely understood. Early diagnosis is essential as agent withdrawal has a significant effect on disease remission.
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![Diffuse tense bullae and blisters on the patient's initial presentation to hospital](1207_Fig1){#f1-1207-1-9079-1-10-20190909}

![Diffuse alopecia on the scalp and jaw with no erythema, scaling or scarring](1207_Fig2){#f2-1207-1-9079-1-10-20190909}

![Sub-epidermal blister with multiple eosinophils](1207_Fig3){#f3-1207-1-9079-1-10-20190909}

![Direct immunofluorescence revealed deposition of IgG and C3 along the basement membrane](1207_Fig4){#f4-1207-1-9079-1-10-20190909}

![Almost complete remission of skin lesions and alopecia 6 weeks after treatment](1207_Fig5){#f5-1207-1-9079-1-10-20190909}

###### 

Characteristics of previous dipeptidyl peptidase-4 inhibitor (DPP-4i)-induced bullous pemphigoid (BP)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Author*                                                    *Patient age and gender*     *DPP-4i*                    *Length of time before BP onset*                                            *Clinical presentation*                                                                                        *Treatment*                                                                                                      *Outcome*
  ----------------------------------------------------------- ---------------------------- --------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  *Mendonça et al.^\[[@b12-1207-1-9079-1-10-20190909]\]^*     *82 M*                       *Linagliptin*               *45 Days*                                                                   *Pruritic cutaneous eruption.*\                                                                                *Prednisone taper over 6 months and etamethasone-gentamicin cream*                                               *Followed for 6 months, no further exacerbations following linagliptin withdrawal*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *77 F*                                                      *Vildagliptin/metformin*     *NA*                        *Mucosal involvement at onset; afterwards, mucosal and cutaneous*           *Prednisone 1 mg/kg/day*                                                                                       *Lost to follow-up*                                                                                              

  *72 F*                                                      *Vildagliptin/metformin*     *3 Months*                  *Pruriginous tense bullae over a urticarial base.*\                         *Prednisone 1 mg/kg/day*                                                                                       *Followed for \>8 months, no further exacerbation*                                                               
                                                                                                                       *No mucosal involvement*                                                                                                                                                                                                                                                                                    

  *Sakai et al.^\[[@b13-1207-1-9079-1-10-20190909]\]^*        *76 F*                       *Linagliptin*               *9 Months*                                                                  *Tense bullae over whole body. No mucosal involvement*                                                         *Topical dexamethasone valerate; minocycline 100 mg daily was added for a while*                                 *Complete remission was achieved at 16 weeks after the discontinuation of linagliptin*

  *Haber et al. ^\[[@b3-1207-1-9079-1-10-20190909]\]^*        *60 M*                       *Linagliptin*               *4 Months*                                                                  *Pruritus and erythematous tense bullae on the limbs.*\                                                        *Topical corticosteroid*                                                                                         *No clinical recurrence of BP during 3 months of follow-up*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *70 F*                                                      *Linagliptin*                *3 Months*                  *Pruritus and tense bullae on the trunk.*\                                  *Topical clobetasol propionate*                                                                                *Followed for 5 months with no clinical recurrence of BP*                                                        
                                                                                                                       *No mucosal involvement*                                                                                                                                                                                                                                                                                    

  *García et al. ^\[[@b14-1207-1-9079-1-10-20190909]\]^*      *74 F*                       *Vildagliptin/metformin*    *12 Months*                                                                 *Pruritic bullous skin lesions on the trunk.*\                                                                 *Oral prednisone for 3 weeks+topical clobetasol*                                                                 *No clinical recurrence after 3 years of follow-up*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *Yoshiji et al. ^\[[@b15-1207-1-9079-1-10-20190909]\]^*     *81 M*                       *Linagliptin*               *9 Months*                                                                  *Erythematous tense bullae over entire body.*\                                                                 *20 mg prednisone, then tapered off*                                                                             *Complete remission 6 weeks after agent withdrawal*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *86 M*                                                      *Linagliptin*                *9 Months*                  *Erythematous tense bullae over entire body.*\                              *Started on 20 mg/day prednisolone, which was tapered to 2 mg/day over 10 months*                              *Complete remission 4 weeks after agent withdrawal*                                                              
                                                                                                                       *No mucosal involvement*                                                                                                                                                                                                                                                                                    

  *83 F*                                                      *Linagliptin, sitagliptin*   *15 Months*                 *Erythematous tense bullae.*\                                               *Prednisolone (15 mg/day), then replaced by IVIG after 3 days because of poor control of BP*                   *Complete remission 2 weeks after agent withdrawal*                                                              
                                                                                                                       *No mucosal involvement*                                                                                                                                                                                                                                                                                    

  *86 F*                                                      *Vildagliptin*               *6 Months*                  *Erythematous tense bullae. No mucosal involvement*                         *Started on 40 mg/day prednisolone and then received IVIG due to poor control of skin symptoms*                *Complete remission 4 weeks after agent withdrawal*                                                              

  *63 M*                                                      *Anagliptin*                 *5 Months*                  *Erythematous bullous eruptions over entire body. No mucosal involvement*   *Prednisolone (20 mg/day), tapered and stopped within 14 days*                                                 *Complete remission 2 weeks after agent withdrawal*                                                              

  *Guliani et al. ^\[[@b16-1207-1-9079-1-10-20190909]\]^*     *69 M*                       *Teneligliptin/metformin*   *4 Months*                                                                  *Erythematous, itchy, fluid-filled lesions. No mucosal involvement*                                            *Topical clobetasol propionate*                                                                                  *The skin lesions improved in a month.*\
                                                                                                                                                                                                                                                                                                                                                                                                                                   *Duration of follow-up unknown*

  *Takama et al. ^\[[@b17-1207-1-9079-1-10-20190909]\]^*      *86 F*                       *Linagliptin, anagliptin*   *6 Weeks*                                                                   *Multiple blisters on both legs.*\                                                                             *Initially topical clobetasol propionate. On day 185, BP relapsed so prednisone 7.5 mg and mizoribine started*   *Complete remission on day 220.*\
                                                                                                                                                                                                   *No mucosal nvolvement*                                                                                                                                                                                                         *Then no relapses up to day 297*

  *Maki et al. ^\[[@b18-1207-1-9079-1-10-20190909]\]^*        *70 M*                       *Teneligliptin*             *4 Weeks*                                                                   *Multiple blisters on the trunk.*\                                                                             *None*                                                                                                           *Followed up for 2 months with no clinical recurrence of BP*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *Harada et al. ^\[[@b19-1207-1-9079-1-10-20190909]\]^*      *78 M*                       *Sitagliptin*               *3 Years*                                                                   *Cutaneous blisters on the bilateral limbs and abdomen*                                                        *Prednisolone 20 mg*                                                                                             *Died on day 14*

  *Esposito et al. ^\[[@b20-1207-1-9079-1-10-20190909]\]^*    *73 F*                       *Linagliptin*               *5 Months*                                                                  *Diffuse bullous rash*                                                                                         *IV methylprednisolone (1 mg/kg/day for 10 days, then tapered) and azathioprine (100 mg/day) for 12 weeks*       *Still in remission at 1-year follow-up*

  *Maki et al. ^\[[@b18-1207-1-9079-1-10-20190909]\]^*        *70 M*                       *Teneligliptin*             *4 Weeks*                                                                   *Multiple blisters on the trunk.*\                                                                             *None*                                                                                                           *Followed up for 2 months with no clinical recurrence of BP*
                                                                                                                                                                                                   *No mucosal involvement*                                                                                                                                                                                                        

  *Harada et al. ^\[[@b19-1207-1-9079-1-10-20190909]\]^*      *78 M*                       *Sitagliptin*               *3 Years*                                                                   *Cutaneous blisters on the bilateral limbs and abdomen*                                                        *Prednisolone 20 mg*                                                                                             *Died on day 14*

  *Esposito et al. ^\[[@b20-1207-1-9079-1-10-20190909]\]^*    *73 F*                       *Linagliptin*               *5 Months*                                                                  *Diffuse bullous rash*                                                                                         *IV methylprednisolone (1 mg/kg/day for 10 days, then tapered) and azathioprine (100 mg/day) for 12 weeks*       *Still in remission at 1-year follow-up*

  *Keseroglu et al. ^\[[@b21-1207-1-9079-1-10-20190909]\]^*   *61 F*                       *Vildagliptin/metformin*    *10 Months*                                                                 *Pruritic vesiculobullous lesions. No mucosal involvement*                                                     *Topical clobetasol*                                                                                             *Remission within 3 weeks.*\
                                                                                                                                                                                                                                                                                                                                                                                                                                   *No further follow-up mentioned*

  *Béné et al. ^\[[@b22-1207-1-9079-1-10-20190909]\]^*        *86 F*                       *Vildagliptin/metformin*    *2 Months*                                                                  *Erythematous bullous eruption, with bullae on healthy skin and extensive erosions on the body*                *Topical clobetasol*                                                                                             *Condition improved after withdrawal of vildagliptin.*\
                                                                                                                                                                                                                                                                                                                                                                                                                                   *Duration of follow-up not mentioned*

  *79 M*                                                      *Vildagliptin/metformin*     *37 Months*                 *Generalized erythematous vesicular bullous eruption*                       *Topical clobetasol*                                                                                           *The lesions recurred at 3 months but improved after discontinuation of vildagliptin.*\                          
                                                                                                                                                                                                                                                                                                                  *The duration of follow-up not mentioned*                                                                        

  *77 F*                                                      *Vildagliptin*               *26 Months*                 *Pruriginous bullous eruption*                                              *Topical clobetasol*                                                                                           *Condition improved after withdrawal of vildagliptin.*\                                                          
                                                                                                                                                                                                                                                                                                                  *The duration of follow up not mentioned*                                                                        

  *Aouidad et al. ^\[[@b23-1207-1-9079-1-10-20190909]\]^*     *61 M*                       *Vildagliptin/metformin*    *5 Months*                                                                  *Pruritus and bullous haemorrhagic lesions over an erythematous base disseminated on the trunk and the limb*   *Topical corticosteroid*                                                                                         *Complete remission 2 weeks after agent withdrawal*

  *Pasmatzi et al. ^\[[@b24-1207-1-9079-1-10-20190909]\]^*    *59 F*                       *Vildagliptin/metformin*    *2 Months*                                                                  *Diffuse bullous eruption mostly on an erythematous base*                                                      *0.5 mg/kg/day methylprednisolone which was tapered over 8 weeks*                                                *Complete remission 10 weeks after agent withdrawal*

  *67 M*                                                      *Vildagliptin/metformin*     *2 Months*                  *Diffuse bullous eruption mostly on an erythematous base*                   *200 mg/day doxycycline for 4 weeks*                                                                           *Complete remission 8 weeks after agent withdrawal*                                                              

  *64 M*                                                      *Linagliptin*                *6 Months*                  *Cutaneous and severe mucosal involvement*                                  *0.3 mg/kg/day oral prednisolone*                                                                              *Improvement of only cutaneous lesions 2 weeks after agent withdrawal.*\                                         
                                                                                                                                                                                                                                                                                                                  *Mucosal lesions improved 2 weeks after starting prednisone. No further follow-up*                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
